Robert Steinbach

List of Publications by Citations

Source: https://exaly.com/author-pdf/9065747/robert-steinbach-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers121
citations7
h-index10
g-index21
ext. papers317
ext. citations7.2
avg, IF2.67
L-index

#	Paper	IF	Citations
17	Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420907803	6.6	26
16	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021 , 53, 1636-1648	36.3	19
15	Structural hallmarks of amyotrophic lateral sclerosis progression revealed by probabilistic fiber tractography. <i>Journal of Neurology</i> , 2015 , 262, 2257-70	5.5	15
14	Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 117	3	8
13	Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model. <i>Human Brain Mapping</i> , 2021 , 42, 737-752	5.9	8
12	Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 783-785	5.5	7
11	Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis. <i>NeuroImage: Clinical</i> , 2020 , 25, 102094	5.3	7
10	Developing a Neuroimaging Biomarker for Amyotrophic Lateral Sclerosis: Multi-Center Data Sharing and the Road to a "Global Cohort". <i>Frontiers in Neurology</i> , 2018 , 9, 1055	4.1	6
9	Classification of amyotrophic lateral sclerosis by brain volume, connectivity, and network dynamics. <i>Human Brain Mapping</i> , 2021 ,	5.9	5
8	Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis <i>JAMA Neurology</i> , 2022 ,	17.2	5
7	Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
6	Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. <i>Frontiers in Neuroscience</i> , 2021 , 15, 651651	5.1	3
5	Poor emotional well-being is associated with rapid progression in amyotrophic lateral sclerosis. <i>ENeurologicalSci</i> , 2019 , 16, 100198	2.1	2
4	Monocyte-Derived Macrophages Contribute to Chitinase Dysregulation in Amyotrophic Lateral Sclerosis: A Pilot Study. <i>Frontiers in Neurology</i> , 2021 , 12, 629332	4.1	2
3	Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. <i>European Journal of Neurology</i> , 2021 , 28, 2582-2595	6	2
2	Emotional Lability at Disease Onset Is an Independent Prognostic Factor of Faster Disease Progression in Amyotrophic Lateral Sclerosis 2020 , 11, 1021-1028		1
1	Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. <i>NeuroImage: Clinical</i> , 2021 , 30, 102674	5.3	O